ImmunityBio Highlights ANKTIVA Data in Lung and Bladder Cancer at ASCO 2026
CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...
NMIBC
Advertisement
AstraZeneca’s Imfinzi Wins FDA Approval in NMIBC
CAMBRIDGE, United Kingdom, May 28, 2026 AstraZeneca has achieved a significant milestone in bladder cancer treatment with the U.S....
ImmunityBio’s ANKTIVA Expansion Review Accepted by FDA
CULVER CITY, Calif., May 19, 2026 ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Johnson & Johnson Survey Highlights Heavy Burden of Bladder Cancer Treatments
WASHINGTON, May 14, 2026 Johnson & Johnson released findings from a groundbreaking global survey revealing the significant physical, emotional,...
UroGen Reports Strong Phase 3 UGN-103 Bladder Cancer Data
PRINCETON, N.J., May 15, 2026 UroGen Pharma Ltd. announced positive six-month results from the ongoing Phase 3 UTOPIA trial,...
Advertisements
CG Oncology Reports Strong Phase 2 Results in High-Risk NMIBC
DALLAS, May 15, 2026 CG Oncology announced positive initial Phase 2 data from the CORE-008 Cohort CX trial, evaluating...
AstraZeneca VOLGA Trial Boosts Bladder Cancer Survival
CAMBRIDGE, UK, May 14, 2026 AstraZeneca announced positive interim results from the global Phase III VOLGA trial, demonstrating that...
Galmed Reports 500% Bioavailability Boost for Aramchol
RAMAT-GAN, Israel, May 14, 2026 Galmed Pharmaceuticals Ltd. announced positive results from its first-in-human pharmacokinetics study evaluating the oral...
Protara Reports Strong Phase 2 NMIBC Trial Results
NEW YORK, May 15, 2026 Protara Therapeutics, Inc. announced positive updated 12-month data from the fully enrolled BCG-Naïve cohort...
ImmunityBio to Present ANKTIVA Data at AUA 2026
CULVER CITY, Calif. – May 5, 2026 ImmunityBio Inc. has announced it will present new comparative clinical data and...
Advertisement
